Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2003-09-05
2008-01-15
O'Hara, Eileen B. (Department: 1647)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C532S001000, C435S183000, C424S094100, C530S350000
Reexamination Certificate
active
07318917
ABSTRACT:
The invention describes the finding that 4-(4-dimethylaminostyrl)-N-methylpyridinium or ASP+is a fluorescent substrate that is transported by several neurotransmitter transporters. Provided are methods for the analysis of neurotransmitter transport and binding using ASP+. The invention also provides rapid methods for screening for modulators of neurotransmitter transport. As neurotransmitter transporter defects are associated with numerous neurological disorders, the invention also provides methods for treating neurotransmitter transport-associated defects/conditions using the modulators identified by the screening methods of the invention.
REFERENCES:
patent: 5312734 (1994-05-01), Uhl et al.
patent: 5418162 (1995-05-01), Blakely et al.
patent: 5424185 (1995-06-01), Lam et al.
patent: 6127133 (2000-10-01), Akong et al.
Schwartz et al., 2003, J. Biol. Chem. 278 (11): 9768-9777.
Brandis, K., 2006, Eukaryon, 2: 22-27.
Peter, et al, 1996, J. Biol. Chem., 271(6): 2979-2986.
Mason, et al, 2005, J. Neurosci. Methods, 143: 3-25.
Schwartz, et al, 2003, J. Biol. Chem., 278(11): 9768-9777.
Apparsundaram et al., “Molecular cloning and characterization of an ι-epinephrine transporter from sympathetic ganglia of the bullfrog, rana catesbiana,”J. Neurosci.,17(8):2691-2702, 1997.
Aston-Jones et al., “Role of locus coeruleus in attention and behavioral flexibility,”Biol. Psychiatry,46:1309-1320, 1999.
Axelrod and Kopin, “The uptake, storage, release and metabolism of noradernaline in sympathetic nerves,”Prog. Brain Res.,31:21-32, 1969.
Bannon, “The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders,”Eur. Neuropsychopharmacol.,11(6):449-455, 2001.
Barker and Blakely, “Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter,”Mol. Pharmacol.,50(4):957-965, 1996.
Barnes, “Breaking the cycle of addiction,”Science,241:1029-1030, 1988.
Beiderman and Spencer, “Attention-deficit/hyperactivity disorder(ADHD) as a noradrenergic disorder,”Biol. Psychiatry,46:1234-1242, 1999.
Blakely and Apparsundaram, “Structural diversity in the catecholamine transporter gene family: molecular cloning and characterization of an L-epinephrine transporter from bullfrog sympathetic ganglia,”Adv. Pharmacol,42:206-210, 1998.
Blakely et al., “Cloning and expression of a functional serotonin transporter from rat brain,”Nature,354:66-70, 1991.
Blundell, “Serotonin manipulations and the structure of feeding behaviour,”Appetite,7(1):39-56, 1986.
Bönisch and Harder, “Binding of 3H-desipramine to the neuronal noraderenaline carrier of rat phaeochromocytoma cells (PC-12 cells),”Naunym Schmeidebergs Arch. Pharmacol.,334:403-411, 1986.
Bönisch, “The transport of (+)-amphetamine by the neuronal noradrenaline carrier,”Naunyn Schmeidebergs Arch. Pharmacol.,327:267-272, 1984.
Bruns et al., “A fast activating presynaptic reuptake current during serotonergic transmission in identified neurons of hiduro,”Neuron,10:559-572, 1993.
Bruns, “Serotonin transport in cultured leech neurons,”Methods Enzymol.,296:593-607, 1998.
Clarkson et al., “Electrophysiological effects of high cocaine concentrations on intact canine heart: evidence for modulation by both heart rate and autonomic nervous system,”Circulation,87:950-962, 1993.
Corey et al., “A cocaine-senstitive drosophila serotonin transporter: cloning, expression, and electrophsiological characterization,”Proc. Natl. Acad. Sci., USA,91:1188-1192, 1994.
Coull et al., “Noradrenergically mediated plasticity in a human attentional neuronal network,”Neuroimage,10:705-715, 1999.
DeFelice, “Visualization of single cell real-time kinetics for norepinephrine transporters using fluorescence microscopy,” manuscript. In Prep. 2003.
DeFelice and Galli, “Electrophysiological analysis of transporter function,”Adv. Pharmacol.,42:186-190, 1998.
DeOliveara et al., “Differences in the temperature dependence of drug interaction with the noradrenaline and serotonin transporters,”Neuropharmacology,28(8):823-828, 1989.
Dow and Kline, “Antidepressant treatment of posttramatic stress disorder and major depression in veterans,”Ann. Clin. Psychiatry,9(1):1-5, 1997.
Fleckenstein et al., “Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function,”Eur. J. Pharmacol.,382:45-49, 1999.
Gainetdinov et al., “Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter,”J. Neurochem.,69:1322-1325, 1997.
Galli et al., “Norepinephrine transporters have channel modes of conduction,”PNAS,93:8671-8676, 1998.
Galli et al., “Sodium-dependent norepinephrine-induced currents in norepinephrine-transporter-transfected HEK-293 cells blocked by cocaine and antidepressants,”J. Exp. Biol.,198(10):2197-2212, 1995.
Gill et al., “Effects of serotonin uptake blockade on food, water, and ethanol consumption in rats,”Alcoholism,11(5):444-449, 1987.
Giros et al., “Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter,”Mol. Pharmacol.,42(3):383-390, 1992.
Giros et al., “Hyperlocation and indifference to cocaine and amphetamine in mice lacking the dopamine transporter,”Nature,379(6566):606-612, 1996.
Glassman et al., “Idiosyncratic pharmacokinetics complicating treatment of major depression in an elderly woman,”J. Nerv. Ment. Dis.,173(9):573-576, 1985.
Hadrich et al., “Synthesis and characterization of fluorescent ligands for the norepinephrine transporter: potential neuroblastoma imaging agents,”J. Med. Chem.,42:3101-3108, 1999.
Hartzell, “Distribution of muscarininc acetylcholine receptors and presynaptic nerve terminals in amphibian heart,”J. Cell Biol.,86:6-20, 1980.
Hatfield and McGaugh, “Norepinephrine infused into the basolateral amygdala posttraining enhancing retention in a spatial water maze task,”Neurobiol. Learn. Mem.,71:232-239, 1999.
Herrara and Banner, “The use and effects of vital fluorescent dyes: observation of motor nerve terminals and satellite cells in living frog muscles,”J. Neurocytol.,19:67-83, 1990.
Herrera et al., “Repeated, in vivo observation of frog neuromuscular junctions: remodeling involves concurrent growth and retraction,”J. Neurocytol.,19:85-99, 1990.
Hohage et al., “Regulation of organic cation transport in IHKE-1 and LLC-PK1 cells. Fluorometric studies with 4-(4-Dimethylaminostyryl)-N-methylpyridinium,”J. Phamacol. Exp. Ther.,286(1):305-310, 1998.
Iverson et al., “Uptake, storage, and metabolism of norepinephrine in tissues of the developing rat,”J. Pharmacol. Exp. Ther.,157(3):509-516, 1967.
Jacob et al., “Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance,”Circulation,99:1706-1712, 1999.
Jones, “Descending noradrenergic influences on pain,”Prog. Brain Res.,88:381-394, 1991.
Kawarai et al., “Structure and organization of the gene encoding human dopamine transporter,”Gene,Aug. 11;195(1):11-8, 1997.
Kitayama et al., “Functional characterization of the splicing variants of human norepinephrine transporter,”Neurosci. Lett.,312(2):108-112, 2001.
Koella, “Serotonin and sleep,” In:Neuronal Seratonin,Osborne et al. (eds.) 153-170, 1988.
Kuhar et al., “The dopamine hypothosis of the reinforcing properties of cocaine,”Trends Neurosci.,14(7):299-302, 1991.
Le Bars, “Serotonin and pain,” In:Neuronal Serotinin,Osborne an
Blakely Randy D.
DeFelice Louis
Schwartz Joel W.
Fulbright & Jaworski L.L.P.
O'Hara Eileen B.
Vanderbilt University
Wegert Sandra
LandOfFree
Rapid assays for neurotransmitter transporters does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rapid assays for neurotransmitter transporters, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rapid assays for neurotransmitter transporters will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3963317